SCHEMBL29566843

SCHEMBL29566843

Cc1cccc(Oc2cc(-c3ccccc3C(C)C)nc(NS(=O)(=O)c3cccc(N)c3)n2)c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NAT1 P18440 1/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ TSHR P16473 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ MAPT P10636 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ NLRP3 Q96P20 1/20 0.36
▸ PIK3C2B O00750 1/20 0.36
▸ PIK3C2G O75747 1/20 0.36
▸ NPY5R Q15761 1/20 0.35
▸ FFAR4 Q5NUL3 1/20 0.35
▸ TDP1 Q9NUW8 2/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24310444 1.00 NAT1 (0.38) NAT1SMN1; SMN2TSHRPOLBMAPT
SCHEMBL26806726 0.93 POLB (0.43) NAT1SMN1; SMN2TSHRPOLBMAPT
SCHEMBL26806752 0.92 NPY5R (0.39) NAT1SMN1; SMN2TSHRPOLBMAPT
SCHEMBL26806725 0.92 PGR (0.43) SMN1; SMN2TSHRPOLBALDH1A1LMNA
SCHEMBL26806723 0.90 PGR (0.39) SMN1; SMN2TSHRPOLBMAPTKMT2A
SCHEMBL26806771 0.90 PGR (0.41) POLBMAPTPIK3C2BPIK3C2G
SCHEMBL26806627 0.89 CHEK1 (0.36) SMN1; SMN2TSHRPOLBMAPTALDH1A1
SCHEMBL26806721 0.88 PIK3C2B (0.39) SMN1; SMN2TSHRPOLBMAPTALDH1A1
SCHEMBL26806728 0.88 PGR (0.42) SMN1; SMN2TSHRPOLBMAPTPIK3C2B
SCHEMBL26806719 0.88 HTR6 (0.43) SMN1; SMN2TSHRPOLBMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225748-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback